- Home
- NBIX vs ROIV Comparison
NBIX vs ROIV Comparison
Compare NBIX & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NBIX
- ROIV
- Stock Information
- Founded
- NBIX 1992
- ROIV 2014
- Country
- NBIX United States
- ROIV United Kingdom
- Employees
- NBIX N/A
- ROIV N/A
- Industry
- NBIX Biotechnology: Biological Products (No Diagnostic Substances)
- ROIV Biotechnology: Pharmaceutical Preparations
- Sector
- NBIX Health Care
- ROIV Health Care
- Exchange
- NBIX Nasdaq
- ROIV Nasdaq
- Market Cap
- NBIX 14.4B
- ROIV 14.0B
- IPO Year
- NBIX 1996
- ROIV N/A
- Fundamental
- Price
- NBIX $150.87
- ROIV $20.63
- Analyst Decision
- NBIX Strong Buy
- ROIV Strong Buy
- Analyst Count
- NBIX 18
- ROIV 8
- Target Price
- NBIX $172.06
- ROIV $21.06
- AVG Volume (30 Days)
- NBIX 1.0M
- ROIV 8.8M
- Earning Date
- NBIX 10-28-2025
- ROIV 11-10-2025
- Dividend Yield
- NBIX N/A
- ROIV N/A
- EPS Growth
- NBIX 12.44
- ROIV N/A
- EPS
- NBIX 4.19
- ROIV N/A
- Revenue
- NBIX $2,682,700,000.00
- ROIV $23,233,000.00
- Revenue This Year
- NBIX $23.68
- ROIV N/A
- Revenue Next Year
- NBIX $18.02
- ROIV $320.50
- P/E Ratio
- NBIX $35.78
- ROIV N/A
- Revenue Growth
- NBIX 19.61
- ROIV N/A
- 52 Week Low
- NBIX $84.23
- ROIV $8.73
- 52 Week High
- NBIX $157.67
- ROIV $20.77
- Technical
- Relative Strength Index (RSI)
- NBIX 59.16
- ROIV 82.87
- Support Level
- NBIX $133.62
- ROIV $19.30
- Resistance Level
- NBIX $157.67
- ROIV $20.09
- Average True Range (ATR)
- NBIX 4.58
- ROIV 0.61
- MACD
- NBIX 0.98
- ROIV 0.10
- Stochastic Oscillator
- NBIX 67.98
- ROIV 94.27
About NBIX Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.